Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In India: A search for more effective tuberculosis drugs

02.02.2009
Rajesh Gokhale has created a compound in his lab in India that stops tuberculosis in its tracks. In a test tube, the molecule hits four of the bacterium's crucial metabolic pathways at the same time, weakening and ultimately destroying the pathogen.

The problem is that Gokhale's compound will not work in humans. Not willing to set aside seven years of work, he has been knocking on the doors of pharmaceutical companies to see if he can get any takers to help design a less toxic version.

Gokhale is pushing himself because he knows if he can design a single drug that is safe and effective, it might one day replace the costly cocktail of drugs that people with tuberculosis must currently take to cure their disease.

While a drug based on Gokhale's ideas is still years away from human testing, it offers a measure of hope that researchers may one day have more modern pharmaceutical "weapons" that can slow down the tuberculosis (TB) pathogen's relentless assault. According to the World Health Organization, TB remains one of the world's top-ten leading causes of death, killing nearly two million people each year. In Gokhale's native India, it kills roughly 1,000 people each day.

"Right now, tuberculosis patients take a cocktail of four drugs, and each inhibits a single enzyme," said Gokhale, a Howard Hughes Medical Institute international research scholar based at the National Institute of Immunology in New Delhi, India. Gokhale's group shows how they designed the molecule that targets multiple enzymes in Mycobacterium tuberculosis in the January 25, 2009, issue of Nature Chemical Biology. "Targeting several enzymes at the same time is a much more efficient approach. Theoretically, patients wouldn't have to take several drugs, they could just take one."

The multi-drug regimen is a major problem for several reasons. It requires TB patients to manage taking four drugs exactly as prescribed over six to nine months. If patients don't take the full course of the medicines, the TB bacteria may develop resistance to the drugs and become even more difficult to treat. To reduce that risk, many countries require that patients go to a clinic so a healthcare professional can watch them take the medication and ensure they are complying with their drug-treatment regimen. This is both expensive and time consuming. Gokhale said that a single drug that targets multiple pathways could save time and money by eliminating the need to take so many drugs over such a long period of time.

To create their new compound, Gokhale and his colleagues exploited an evolutionary quirk in the way Mycobacterium tuberculosis builds the lipid layer that coats its surface. Unlike other organisms, M. tuberculosis displays a suite of complex lipids on its outer membrane. Some scientists have suggested that these long lipid molecules contribute to the bacteria's ability to maintain long-term infections by confusing the host's immune system.

"The complex lipids displayed by Mycobacterium tuberculosis are a big factor in its pathogenicity and virulence," Gokhale said. "But what was not known is how they were made by the organism."

For the past seven years, Gokhale and his colleagues have studied the intricate metabolic pathways that Mycobacterium tuberculosis employs to build complex lipids. He has come to regard the TB bacteria as a "chemical factory" where complex machines, in the form of enzymes, work together to link simple building blocks—called fatty acids—into long chains. In 2004, Gokhale and his colleagues found a new class of enzymes that are critical for an early phase of the lipid-building process. Called fatty acyl-AMP ligases (FAALs), these enzymes tweak fatty acids so that a second class of enzymes can string them together like bulbs on a strand of Christmas lights.

In their most recent study, Gokhale and his colleagues show that particular molecules that inhibit FAALs also inhibit other, similarly-shaped enzymes involved in the assembly line that is lipid use and degradation. These enzymes are required during the life cycle of the TB bacterium in the humans. "A major challenge has been to develop drugs that could target different stages disease," Gokhale said. "Since this single molecule could potentially grind the assembly line to a halt at different stages of infection, this approach provides tremendous opportunity to develop unique antituberculosis drugs."

Gokhale has collaborated with a colleague at a colleague at the Centre for Cellular and Molecular Biology in Hyderabad, Rajan Sankaranarayanan, to examine the three-dimensional structure of the molecule. This will give his group the opportunity to modify the molecule or develop a new one that is less toxic and better targets the TB bacteria. Gokhale said that the drug industry is finally waking up to the idea that a single drug can work on multiple metabolic pathways, rather than making a molecule that acts in a very specific way on a single target.

"The 'one disease–one drug–one target' paradigm that has dominated thinking in the pharmaceutical industry for the past few decades is now being increasingly challenged by the discovery of compounds that bind to more than one target," Gokhale said. "That's the direction we're heading in trying to develop a single chemical entity that could simultaneously target a family of enzymes in TB."

Andrea Widener | EurekAlert!
Further information:
http://www.hhmi.org

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>